Innate Pharma works on an innovative approach against cancer and inflammatory diseases: monoclonal antibodies designed to stimulate anti-tumor activity of NK cells and other cells of the innate immune system.
Immuno-oncology is changing cancer treatment by harnessing the power of the body’s immune system to recognize and kill cancer cells. This approach aims at restoring immune surveillance and can lead to durable responses in some patients who have failed all available conventional therapies. One of the greatest advances in immuno-oncology involves the use of checkpoint inhibitors. Checkpoint inhibitors block immune checkpoint receptors, which are molecules on the surface of immune cells that inhibit the ability of effector cells, such as T cells and NK cells, to kill cancer cells. Cancer cells can exploit immune checkpoints to evade detection by the immune system. Antibodies that block specific immune checkpoints can re-enable the body’s immune cells to recognize and kill cancer cells that would otherwise go undetected.
With three first-in-class checkpoint inhibitors in clinical trials and a portfolio of preclinical antibodies, Innate Pharma benefits from a leadership position in the development of checkpoint inhibitors designed to stimulate innate immune cells.
Targeting immunity cells
Innate Pharma is a leader in the development of checkpoint inhibitors